Level C· Early human research exploring benefitsProspective StudyPubMed

Deoxycholic acid ameliorates postmenopausal osteoporosis by rebalancing BMSC differentiation and suppressing NF-κB signaling.

Wang C., Liu L., Wu J., Huang X., Liu J., Yi Y.

Prospective Study on Back & Spine, Hip, published in J Nutr Biochem (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
J Nutr Biochem (2026)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
42263788
DOI
10.1016/j.jnutbio.2026.110438

Abstract (original English)

Postmenopausal osteoporosis (PMOP) represents a significant global health issue associated with aging, primarily driven by estrogen deficiency. Although the gut-bone axis has garnered increasing attention, the specific bioactive metabolites and molecular mechanisms linking gut dysbiosis to bone loss remain to be fully elucidated. In this study, we investigated the gut-bile acid-bone axis by integrating clinical data with mechanistic studies in an ovariectomized mouse model. Clinically, serum total bile acid levels were positively correlated with bone mineral density in PMOP patients. In ovariectomized mice, estrogen withdrawal induced alterations in the abundance of gut microbiota involved in secondary bile acid biosynthesis, including Clostridium, Bifidobacterium, and Bacteroides, resulting in decreased serum deoxycholic acid (DCA) levels. Notably, Mendelian randomization analysis provided genetic evidence supporting a causal relationship between serum DCA levels and lumbar spine bone mineral density. Therapeutically, DCA supplementation effectively mitigated trabecular bone loss and improved microarchitectural integrity, while simultaneously regulating white adipose metabolism and hepatic bile acid synthesis. Mechanistically, DCA restores the balance of bone remodeling by promoting osteoblastogenesis over adipogenesis in bone marrow mesenchymal stem cells and inhibiting osteo

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
AnimalsFemaleNF-kappa BHumansSignal TransductionOsteoporosis, PostmenopausalCell DifferentiationDeoxycholic AcidBone DensityMesenchymal Stem Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research